All eyes still on AI and semiconductors 👀

Market looking HOT today!                                                                                                                                                                                                                                                                                                                                                                                                                 March 04, 2024 All eyes still on AI and semiconductors 👀 *Promoted by Sica Media Here’s to a great week ahead in the Markets. … and thank YOU for being a loyal 360 reader! Be the best prepared trader on the Street! FOCUS LIST🔎 RNLX - AI biotech up over 40% in the pre-market on new news, AI sympathy AKRO - Up over 30% after lead drug helps reduce scarring in fatty liver disease patients SMCI - Up over 16% in pre on S&P 500 inclusion news SPOTLIGHT 💡 *Promoted by Sica Media ✅ As a small-cap and a biotech stock, NeuroOne Medical (NMTC) checks off two of the major trends we see for this week. After a series of back-and-forth price moves over the last couple of months, NMTC has quietly started to build a base above the “magical $1 level”and just fired off a “Gamma Trigger” signal on Friday. In the chart below, you’ll see where I think the recent support/resistance levels have been. If this “Gamma Trigger” move continues to carry NMTC higher, I think it is very important to keep an eye on the $1.40 level, which has shown to be resistance lately.  If that is broken through convincingly, it could then act as a new support level. The cool thing is that after the $1.40 level, the next serious resistance point is all the way at $2, which NMTC has tested a few times in the last year. However, if the move fails, I would keep a close eye on $1.05, which has been the support level on the downside. To learn what this company does, [you can visit their website here]( and read [this recent company report](. No matter what you end up trading this week, it is very important to come to the market with a solid trade plan. Only trade with money you can afford to lose, and always make sure to carefully read all disclaimers and research you can get your hands on. *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. HOTLIST🔥 RNLX - AI biotech up over 40% on new news, AI sympathy Renalytix Plc (RNLX) develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. Artificial intelligence (AI) related names such as BBAI and SOUN have been in play recently and it looks as though traders have turned their attention to RNLX this morning. There seems to have been no apparent news for the company this morning. The stock traded up over 40% in the pre-market. The $1.35 area has acted as support so far in the pre-market and will be an important level to watch. Above it, targets to the upside are $1.50, $1.60, $1.67, $1.73, $1.80 and then the pre-market high at $1.92. Beyond that, $2 and $2.40 and $3 come into play. Below $1.35, targets to the downside are $1.30, $1.20 and then a gap to fill at $1.04. AKRO - Up over 30% after lead drug helps reduce scarring in fatty liver disease patients Akero Therapeutics, Inc. (AKRO) is a clinical-stage company that engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. This morning, [the company announced]( statistically significant histological improvements in its Phase 2b HARMONY Study. After 96 weeks, biopsies of patients showed that the drug, Efruxifermin, helped to reduce scarring in the liver by at least 1 stage in 75% of patients who took the higher dose, and in 46% of those on the lower dose, compared to 24% for placebo. The rates of reduction in scarring was significantly higher at 96 weeks than that at 24 weeks, showing sustained improvement due to the drug. The stock traded up over 30% in the pre-market after the news. There has been support at the $33.50 area so far in the pre-market, and that will be an important level to watch. Above it, targets to the upside are $37, $40, $45, $50 and then the pre-market high at $56.10. Below $33.50, targets to the downside are $31.90, $30 and then a gap fill at $27.81. SPOTLIGHT 💡 February Closing … Patience Paid Off! Never. Give. Up. 💪 *Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically. [Join Jeff on his next $10,000 Mission]( Jeff to make 10 LIVE trades with members in March— first one is TODAY! Must be in Alpha Hunter to access the Alpha Chamber SMCI - Up over 16% in pre on S&P 500 inclusion news Super Micro Computer, Inc. develops and manufactures high performance server and storage solutions based on modular and open architecture in the United States and internationally. Its solutions range from complete server, storage systems, modular blade servers, blades, workstations, full racks, networking devices, server sub-systems, server management software, and security software. In the after-hours Friday, [it was announced]( that as part of the quarterly rebalance of the most widely followed stocks index, SMCI and Deckers Outdoor Corp will join the S&P 500 on Monday, March 18, replacing Whirlpool Corp and Zion Bancorp. The addition into the S&P500 has sent the AI server maker soaring, up over 16% in the pre-market after the news. $1077.87 is the all-time highs for SMCI and will be the first major target for bulls. Above it, targets to the upside are around numbers such as $1100, $1110, $1120, $1150 and $1200. Below $1077.87, targets to the downside are $1060, $1040, $1020, $1000, $980, $920 and $900.  MARKET NEWS 📰 More Resources💥 [Need improvement? Learn from Jason’s favorite trading ideas under $10]( [Get instant access to Jeff Bishop's top trading ideas]( 💡[Get the hottest stock ideas in Bright Ideas]( 👉 Text “RAGE” to 1-(888) 404-5747 to get all of our latest HOT STOCK ideas delivered right to your phone (make sure you put the 1 in). ! Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull DISCLAIMER *PAID ADVERTISEMENT. Raging Bull has currently been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. for a one-day marketing program. Raging Bull was previously paid five thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. from a period beginning on December 12 through December 12, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of NeuroOne Medical Technologies Corp., increased trading volume, and possibly an increased share price of NeuroOne Medical Technologies Corp.’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in NeuroOne Medical Technologies Corp., though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States of America